Recent studies demonstrate that contrary to the expected effect of CDKN2A/B loss, elevated levels of CDKN2A mRNA are associated with lower PFS and more malignant molecular and methylation classes in CDKN2A/B intact/wild-type meningiomas [46]. This evidence concerns the gene CDKN2A and meningioma.